Benzbromarone, Quercetin, and Folic Acid Inhibit Amylin Aggregation
Abstract
:1. Introduction
2. Results and Discussion
2.1. Identification of Inhibitor Candidates
2.2. Identification of True Inhibitors by Turbidity and Transmission Electron Microscopy (TEM) Analyses
2.3. Chemical Nature and Cellular Toxicity of the Three Inhibitors
2.4. Partial Inhibitory Effect of Quercetin on the Cytotoxicity Induced by Amylin (8–37) in Rat Insulinoma Pancreatic (RIN-m5F) Cells
2.5. Some Previous Evidences Relating Benzbromarone, Quercetin or Folic Acid with Type II Diabetes
3. Materials and Methods
3.1. Materials
3.2. High Throughput Screening
3.3. Turbidity Test
3.4. Transmission Electron Microscopy
3.5. Cytotoxicity Assays of Aggregation Inhibitors in HeLa Cells
3.6. Cytotoxicity Assays of Amylin (8–37) in RIN-m5F Cells in Absence or Presence of Aggregation Inhibitors
4. Conclusions
Supplementary Materials
Acknowledgments
Author Contributions
Conflicts of Interest
References
- Danaei, G.; Finucane, M.M.; Lu, Y.; Singh, G.M.; Cowan, M.J.; Paciorek, C.J.; Lin, J.K.; Farzadfar, F.; Khang, Y.H.; Stevens, G.A.; et al. National, regional, and global trends in fasting plasma glucose and diabetes prevalence since 1980: Systematic analysis of health examination surveys and epidemiological studies with 370 country-years and 2.7 million participants. Lancet 2011, 378, 31–40. [Google Scholar] [CrossRef]
- National Diabetes Statistics Report, 2014. Available online: http://www.cdc.gov/diabetes/pubs/statsreport14/national-diabetes-report-web.pdf (accessed on 15 June 2016).
- Marzban, L.; Park, K.; Verchere, C.B. Islet amyloid polypeptide and type 2 diabetes. Exp. Gerontol. 2003, 38, 347–351. [Google Scholar] [CrossRef]
- Kumar, V.; Tausto, N.; Abbas, A. Robbins and Cotran Pathologic Basis of Disease, 7th ed.; Saunders: Philadelphia, PA, USA, 2005. [Google Scholar]
- Hayden, M.R. Pancreatic islet amyloid in type 2 diabetes mellitus: A clinical and historical review. Mol. Med. 2002, 99, 495–498. [Google Scholar]
- Westermark, P.; Wilander, E. The influence of amyloid deposits on the islet volume in maturity onset diabetes mellitus. Diabetologia 1978, 15, 417–421. [Google Scholar] [CrossRef] [PubMed]
- Mirzabekov, T.A.; Lin, M.C.; Kagan, B.L. Pore formation by the cytotoxic islet amyloid peptide amylin. J. Biol. Chem. 1996, 271, 1988–1992. [Google Scholar] [PubMed]
- Westermark, P.; Wernstedt, C.; Wilander, E.; Hayden, D.W.; O’Brien, T.D.; Johnson, K.H. Amyloid fibrils in human insulinoma and islets of langerhans of the diabetic cat are derived from a neuropeptide-like protein also present in normal islet cells. Proc. Natl. Acad. Sci. USA 1987, 84, 3881–3885. [Google Scholar] [CrossRef] [PubMed]
- Westermark, P.; Engstrom, U.; Johnson, K.H.; Westermark, G.T.; Betsholtz, C. Islet amyloid polypeptide: Pinpointing amino acid residues linked to amyloid fibril formation. Proc. Natl. Acad. Sci. USA 1990, 87, 5036–5040. [Google Scholar] [CrossRef] [PubMed]
- Moriarty, D.F.; Raleigh, D.P. Effects of sequential proline substitutions on amyloid formation by human amylin 20–29. Biochemistry 1999, 38, 1811–1818. [Google Scholar] [CrossRef] [PubMed]
- Kelly, J.W. The alternative conformations of amyloidogenic proteins and their multi-step assembly pathways. Curr. Opin. Struct. Biol. 1998, 8, 101–106. [Google Scholar] [CrossRef]
- Luca, S.; Yau, W.M.; Leapman, R.; Tycko, R. Peptide conformation and supramolecular organization in amylin fibrils: Constraints from solid-state NMR. Biochemistry 2007, 46, 13505–13522. [Google Scholar] [CrossRef] [PubMed]
- Serpell, L.C.; Sunde, M.; Benson, M.D.; Tennent, G.A.; Pepys, M.B.; Fraser, P.E. The protofilament substructure of amyloid fibrils. J. Mol. Biol. 2000, 300, 1033–1039. [Google Scholar] [CrossRef] [PubMed]
- Sunde, M.; Blake, C.C. From the globular to the fibrous state: Protein structure and structural conversion in amyloid formation. Q. Rev. Biophys. 1998, 31, 1–39. [Google Scholar] [CrossRef] [PubMed]
- Anguiano, M.; Nowak, R.J.; Lansbury, P.T., Jr. Protofibrillar islet amyloid polypeptide permeabilizes synthetic vesicles by a pore-like mechanism that may be relevant to type ii diabetes. Biochemistry 2002, 41, 11338–11343. [Google Scholar] [CrossRef] [PubMed]
- Haataja, L.; Gurlo, T.; Huang, C.J.; Butler, P.C. Islet amyloid in type 2 diabetes, and the toxic oligomer hypothesis. Endocr. Rev. 2008, 29, 303–316. [Google Scholar] [CrossRef] [PubMed]
- Janson, J.; Ashley, R.H.; Harrison, D.; McIntyre, S.; Butler, P.C. The mechanism of islet amyloid polypeptide toxicity is membrane disruption by intermediate-sized toxic amyloid particles. Diabetes 1999, 48, 491–498. [Google Scholar] [CrossRef] [PubMed]
- Konarkowska, B.; Aitken, J.F.; Kistler, J.; Zhang, S.; Cooper, G.J. The aggregation potential of human amylin determines its cytotoxicity towards islet β-cells. FEBS J. 2006, 273, 3614–3624. [Google Scholar] [CrossRef] [PubMed]
- Lin, C.Y.; Gurlo, T.; Kayed, R.; Butler, A.E.; Haataja, L.; Glabe, C.G.; Butler, P.C. Toxic human islet amyloid polypeptide (H-IAPP) oligomers are intracellular, and vaccination to induce anti-toxic oligomer antibodies does not prevent h-iapp-induced β-cell apoptosis in H-IAPP transgenic mice. Diabetes 2007, 56, 1324–1332. [Google Scholar] [CrossRef] [PubMed]
- Ritter, C.; Maddelein, M.L.; Siemer, A.B.; Luhrs, T.; Ernst, M.; Meier, B.H.; Saupe, S.J.; Riek, R. Correlation of structural elements and infectivity of the HET-S prion. Nature 2005, 435, 844–848. [Google Scholar] [CrossRef] [PubMed]
- Necula, M.; Kayed, R.; Milton, S.; Glabe, C.G. Small molecule inhibitors of aggregation indicate that amyloid β oligomerization and fibrillization pathways are independent and distinct. J. Biol. Chem. 2007, 282, 10311–10324. [Google Scholar] [CrossRef] [PubMed]
- Glenner, G.G.; Wong, C.W. Alzheimer’s disease and down’s syndrome: Sharing of a unique cerebrovascular amyloid fibril protein. Biochem. Biophys. Res. Commun. 1984, 122, 1131–1135. [Google Scholar] [CrossRef]
- Iwai, A.; Masliah, E.; Yoshimoto, M.; Ge, N.; Flanagan, L.; de Silva, H.A.; Kittel, A.; Saitoh, T. The precursor protein of non-Aβ component of Alzheimer’s disease amyloid is a presynaptic protein of the central nervous system. Neuron 1995, 14, 467–475. [Google Scholar] [CrossRef]
- McLaurin, J.; Kierstead, M.E.; Brown, M.E.; Hawkes, C.A.; Lambermon, M.H.; Phinney, A.L.; Darabie, A.A.; Cousins, J.E.; French, J.E.; Lan, M.F.; et al. Cyclohexanehexol inhibitors of Aβ aggregation prevent and reverse Alzheimer phenotype in a mouse model. Nat. Med. 2006, 12, 801–808. [Google Scholar] [CrossRef] [PubMed]
- Adlard, P.A.; Cherny, R.A.; Finkelstein, D.I.; Gautier, E.; Robb, E.; Cortes, M.; Volitakis, I.; Liu, X.; Smith, J.P.; Perez, K.; et al. Rapid restoration of cognition in Alzheimer’s transgenic mice with 8-hydroxy quinoline analogs is associated with decreased interstitial Aβ. Neuron 2008, 59, 43–55. [Google Scholar] [CrossRef] [PubMed]
- Ma, K.; Thomason, L.A.; McLaurin, J. Scyllo-inositol, preclinical, and clinical data for Alzheimer’s disease. Adv. Pharmacol. 2012, 64, 177–212. [Google Scholar] [PubMed]
- Wischik, C.M.; Staff, R.T.; Wischik, D.J.; Bentham, P.; Murray, A.D.; Storey, J.M.; Kook, K.A.; Harrington, C.R. Tau aggregation inhibitor therapy: An exploratory phase 2 study in mild or moderate Alzheimer’s disease. J. Alzheimer’s Dis. 2015, 44, 705–720. [Google Scholar]
- Abian, O.; Vega, S.; Sancho, J.; Velazquez-Campoy, A. Allosteric inhibitors of the NS3 protease from the hepatitis c virus. PLoS ONE 2013, 8, e69773. [Google Scholar] [CrossRef] [PubMed]
- Conesa, C.; Doss, M.X.; Antzelevitch, C.; Sachinidis, A.; Sancho, J.; Carrodeguas, J.A. Identification of specific pluripotent stem cell death—Inducing small molecules by chemical screening. Stem Cell Rev. 2012, 8, 116–127. [Google Scholar] [CrossRef] [PubMed]
- Cremades, N.; Velazquez-Campoy, A.; Martinez-Julvez, M.; Neira, J.L.; Perez-Dorado, I.; Hermoso, J.; Jimenez, P.; Lanas, A.; Hoffman, P.S.; Sancho, J. Discovery of specific flavodoxin inhibitors as potential therapeutic agents against helicobacter pylori infection. ACS Chem. Biol. 2009, 4, 928–938. [Google Scholar] [CrossRef] [PubMed]
- Lopez, L.C.; Dos-Reis, S.; Espargaro, A.; Carrodeguas, J.A.; Maddelein, M.L.; Ventura, S.; Sancho, J. Discovery of novel inhibitors of amyloid β-peptide 1-42 aggregation. J. Med. Chem. 2012, 55, 9521–9530. [Google Scholar] [CrossRef] [PubMed]
- Pey, A.L.; Ying, M.; Cremades, N.; Velazquez-Campoy, A.; Scherer, T.; Thony, B.; Sancho, J.; Martinez, A. Identification of pharmacological chaperones as potential therapeutic agents to treat phenylketonuria. J. Clin. Investig. 2008, 118, 2858–2867. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Sanchez de Groot, N.; Pallares, I.; Aviles, F.X.; Vendrell, J.; Ventura, S. Prediction of “hot spots” of aggregation in disease-linked polypeptides. BMC Struct. Biol. 2005, 5, 18. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Jaikaran, E.T.; Higham, C.E.; Serpell, L.C.; Zurdo, J.; Gross, M.; Clark, A.; Fraser, P.E. Identification of a novel human islet amyloid polypeptide β-sheet domain and factors influencing fibrillogenesis. J. Mol. Biol. 2001, 308, 515–525. [Google Scholar] [CrossRef] [PubMed]
- LeVine, H., 3rd. Thioflavine t interaction with synthetic Alzheimer’s disease β-amyloid peptides: Detection of amyloid aggregation in solution. Protein Sci. 1993, 2, 404–410. [Google Scholar] [CrossRef] [PubMed]
- Lorenzo, A.; Yankner, B.A. Β-amyloid neurotoxicity requires fibril formation and is inhibited by congo red. Proc. Natl. Acad. Sci. USA 1994, 91, 12243–12247. [Google Scholar] [CrossRef] [PubMed]
- Trikha, S.; Jeremic, A.M. Clustering and internalization of toxic amylin oligomers in pancreatic cells require plasma membrane cholesterol. J. Biol. Chem. 2011, 286, 36086–36097. [Google Scholar] [CrossRef] [PubMed]
- Kumar, S.; Ng, J.; Gow, P. Benzbromarone therapy in management of refractory gout. N. Z. Med. J. 2005, 118, U1528. [Google Scholar] [PubMed]
- Cai, H.Y.; Wang, T.; Zhao, J.C.; Sun, P.; Yan, G.R.; Ding, H.P.; Li, Y.X.; Wang, H.Y.; Zhu, W.L.; Chen, K.X. Benzbromarone, an old uricosuric drug, inhibits human fatty acid binding protein 4 in vitro and lowers the blood glucose level in db/db mice. Acta Pharmacol. Sin. 2013, 34, 1397–1402. [Google Scholar] [CrossRef] [PubMed]
- Sudchada, P.; Saokaew, S.; Sridetch, S.; Incampa, S.; Jaiyen, S.; Khaithong, W. Effect of folic acid supplementation on plasma total homocysteine levels and glycemic control in patients with type 2 diabetes: A systematic review and meta-analysis. Diabetes Res. Clin. Pract. 2012, 98, 151–158. [Google Scholar] [CrossRef] [PubMed]
- Mangoni, A.A.; Sherwood, R.A.; Asonganyi, B.; Swift, C.G.; Thomas, S.; Jackson, S.H. Short-term oral folic acid supplementation enhances endothelial function in patients with type 2 diabetes. Am. J. Hypertens. 2005, 18, 220–226. [Google Scholar] [CrossRef] [PubMed]
- Aguirre, L.; Arias, N.; Macarulla, M.T.; Gracia, A.; Portillo, M.P. Beneficial effects of quercetin on obesity and diabetes. Open Nutraceuticals J. 2011, 4, 189–198. [Google Scholar]
- Bardy, G.; Virsolvy, A.; Quignard, J.F.; Ravier, M.A.; Bertrand, G.; Dalle, S.; Cros, G.; Magous, R.; Richard, S.; Oiry, C. Quercetin induces insulin secretion by direct activation of l-type calcium channels in pancreatic β cells. Br. J. Pharmacol. 2013, 169, 1102–1113. [Google Scholar] [CrossRef] [PubMed]
- Coskun, O.; Kanter, M.; Korkmaz, A.; Oter, S. Quercetin, a flavonoid antioxidant, prevents and protects streptozotocin-induced oxidative stress and β-cell damage in rat pancreas. Pharmacol. Res. 2005, 51, 117–123. [Google Scholar] [CrossRef] [PubMed]
- Kim, J.H.; Kang, M.J.; Choi, H.N.; Jeong, S.M.; Lee, Y.M.; Kim, J.I. Quercetin attenuates fasting and postprandial hyperglycemia in animal models of diabetes mellitus. Nutr. Res. Pract. 2011, 5, 107–111. [Google Scholar] [CrossRef] [PubMed]
- Mahesh, T.; Menon, V.P. Quercetin allievates oxidative stress in streptozotocin-induced diabetic rats. Phytother. Res. 2004, 18, 123–127. [Google Scholar] [CrossRef] [PubMed]
- Vessal, M.; Hemmati, M.; Vasei, M. Antidiabetic effects of quercetin in streptozocin-induced diabetic rats. Comp. Biochem. Physiol. Toxicol. Pharmacol. 2003, 135C, 357–364. [Google Scholar] [CrossRef]
- Adewole, S.O.; Caxton-Martins, E.A.; Ojewole, J.A. Protective effect of quercetin on the morphology of pancreatic β-cells of streptozotocin-treated diabetic rats. Afr. J. Tradit. Complement. Altern. Med. 2006, 4, 64–74. [Google Scholar] [CrossRef] [PubMed]
- Ramachandra, R.; Shetty, A.K.; Salimath, P.V. Quercetin alleviates activities of intestinal and renal disaccharidases in streptozotocin-induced diabetic rats. Mol. Nutr. Food Res. 2005, 49, 355–360. [Google Scholar] [CrossRef] [PubMed]
- Jeong, S.M.; Kang, M.J.; Choi, H.N.; Kim, J.H.; Kim, J.I. Quercetin ameliorates hyperglycemia and dyslipidemia and improves antioxidant status in type 2 diabetic db/db mice. Nutr. Res. Pract. 2012, 6, 201–207. [Google Scholar] [CrossRef] [PubMed]
- ClinicalTrials.gov. Available online: http://clinicaltrials.gov/show/NCT01839344 (accessed on 31 May 2016).
- Noor, H.; Cao, P.; Raleigh, D.P. Morin hydrate inhibits amyloid formation by islet amyloid polypeptide and disaggregates amyloid fibers. Protein Sci. 2012, 21, 373–382. [Google Scholar] [CrossRef] [PubMed]
- Zelus, C.; Fox, A.; Calciano, A.; Faridian, B.S.; Nogaj, L.A.; Moffet, D.A. Myricetin inhibits islet amyloid polypeptide (IAPP) aggregation and rescues living mammalian cells from iapp toxicity. Open Biochem. J. 2012, 6, 66–70. [Google Scholar] [CrossRef] [PubMed]
- Sato, M.; Murakami, K.; Uno, M.; Nakagawa, Y.; Katayama, S.; Akagi, K.; Masuda, Y.; Takegoshi, K.; Irie, K. Site-specific inhibitory mechanism for amyloid β42 aggregation by catechol-type flavonoids targeting the lys residues. J. Biol. Chem. 2013, 288, 23212–23224. [Google Scholar] [CrossRef] [PubMed]
- Gazova, Z.; Siposova, K.; Kurin, E.; Mucaji, P.; Nagy, M. Amyloid aggregation of lysozyme: The synergy study of red wine polyphenols. Proteins 2013, 81, 994–1004. [Google Scholar] [CrossRef] [PubMed]
- Wang, J.B.; Wang, Y.M.; Zeng, C.M. Quercetin inhibits amyloid fibrillation of bovine insulin and destabilizes preformed fibrils. Biochem. Biophys. Res. Commun. 2011, 415, 675–679. [Google Scholar] [CrossRef] [PubMed]
- Zhu, M.; Han, S.; Fink, A.L. Oxidized quercetin inhibits α-synuclein fibrillization. Biochim. Biophys. Acta 2013, 1830, 2872–2881. [Google Scholar] [CrossRef] [PubMed]
- Di Giovanni, S.; Eleuteri, S.; Paleologou, K.E.; Yin, G.; Zweckstetter, M.; Carrupt, P.A.; Lashuel, H.A. Entacapone and tolcapone, two catechol o-methyltransferase inhibitors, block fibril formation of α-synuclein and β-amyloid and protect against amyloid-induced toxicity. J. Biol. Chem. 2010, 285, 14941–14954. [Google Scholar] [CrossRef] [PubMed]
Aggregation Inhibitors | Structure |
---|---|
Benzbromarone: 3-(3,5-dibromo-4-hydroxybenzoyl)-2-ethylbenzofuran; (3,5-dibromo-4-hydroxyphenyl)(2-ethyl-1-benzofuran-3-yl)methanone | |
Quercetin dihydrate: 3,3′,4′,5,7-pentahydroxyflavone dihydrate; 2-(3,4-dihydroxyphenyl)-3,5,7-trihydroxy-4H-1-benzopyran-4-one dihydrate | |
Folic acid: pteroyl-l-glutamic acid pteroyl-l-glutamate |
© 2016 by the authors; licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC-BY) license (http://creativecommons.org/licenses/by/4.0/).
Share and Cite
López, L.C.; Varea, O.; Navarro, S.; Carrodeguas, J.A.; Sanchez de Groot, N.; Ventura, S.; Sancho, J. Benzbromarone, Quercetin, and Folic Acid Inhibit Amylin Aggregation. Int. J. Mol. Sci. 2016, 17, 964. https://doi.org/10.3390/ijms17060964
López LC, Varea O, Navarro S, Carrodeguas JA, Sanchez de Groot N, Ventura S, Sancho J. Benzbromarone, Quercetin, and Folic Acid Inhibit Amylin Aggregation. International Journal of Molecular Sciences. 2016; 17(6):964. https://doi.org/10.3390/ijms17060964
Chicago/Turabian StyleLópez, Laura C., Olga Varea, Susanna Navarro, José A. Carrodeguas, Natalia Sanchez de Groot, Salvador Ventura, and Javier Sancho. 2016. "Benzbromarone, Quercetin, and Folic Acid Inhibit Amylin Aggregation" International Journal of Molecular Sciences 17, no. 6: 964. https://doi.org/10.3390/ijms17060964